THRIVE is the first phase 2 study to evaluate the VIASKIN Peanut Patch in infants aged 6 to 12 months with peanut allergy. Investigators will assess whether early epicutaneous immunotherapy can enable ...
THRIVE is the first study to evaluate the VIASKIN Peanut Patch in infants aged 6 to 12 months with confirmed peanut allergy. Investigators hope intervention during infancy may alter the long-term ...
Outdoor meals raise the risk of food poisoning. Here's how families can keep picnics, cookouts and beach days food-safe, from coolers to grill temperatures. Summer means more meals outside — at the ...
The July 1, 2026 decision makes exagamglogene autotemcel the first gene therapy approved for SCD in children younger than 12 years. The FDA has issued a supplemental approval for Casgevy ...
Professor of Pediatrics, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, and Attending Physician, Pediatric Emergency Medicine, Nemours/Alfred I duPont ...
The AAP now recommends universal iron deficiency screening for all infants between 9 and 18 months and for all adolescents at least 1 year after menarche but no later than age 14. Updated ferritin ...
The FDA has granted Orphan Drug Designation to para-chloro-phenylalanine (pCPA) for monoamine oxidase deficiency (MAOD), a rare X-linked neurodevelopmental disorder associated with impaired monoamine ...
Researchers found evidence that childhood influences may contribute to 85 adult health diagnoses, including tobacco use disorder, heart disease, digestive disorders, and urinary conditions. Later age ...
Setmelanotide reduced BMI measures, fat mass, and hyperphagia scores in interim phase 2 Prader-Willi syndrome data. Rhythm Pharmaceuticals reported 6-month interim data from an ongoing phase 2 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results